Memory and Mental Health in Aging

NCT02988908 | Completed Phase 4

• 3 other identifiers: SU-06302009-2820R01MH035182eprotocol #7530
• Study Type: interventional
• Target: 198
• Locations: 1 country
• Sites: 1

Brief Summary

A comparison of memory training with and without donepezil.

Conditions

Memory

Outcome Measures

Primary Outcomes (2)

• Change in recall of Word List over time

  Each participant was given a list of 16 words. Participants had 4 minutes to memorize the words in order. Short-term recall was tested after 5 minutes exposure to a distractor task and delayed recall was tested after 30 minutes. At recall participants were asked to recall as many words as they could remember in the order the words were presented.

  measured at baseline, Week 13 (before training), Week 14 (at end of training), and Week 52

• Change in recall of Name-Face pairs over time

  Each participant was shown 12 name-face pairs for 1 minute. Recall was tested immediately after presentation of all 12 name-face pairs (faces were shown for 1 minute and participant was asked to supply the name).

  measured at baseline, Week 13 (before training), Week 14 (at end of training), and Week 52

Secondary Outcomes (4)

• Change in Symbol Digit score over time

  measured at baseline, Week 13, and Week 52

• Change in Digit Span score over time

  measured at baseline, Week 13, and Week 52

• Change in Medical Outcomes Study Functioning and Well-being Profile over time

  measured at baseline, Week 13, and Week 52

• Change in Everyday Problems Test score over time

  measured at baseline, Week 13 (before training), and Week 52

Study Arms (2)

Drug: Donepezil

EXPERIMENTAL

Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial. Participants also received 2 weeks of memory training at weeks 13-14

Drug: Donepezil

Placebo (Control)

PLACEBO COMPARATOR

Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial. Participants also received 2 weeks of memory training at weeks 13-14

Drug: Placebos

Interventions

Donepezil DRUG

Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial. Participants also received 2 weeks of memory training at weeks 13-14

Also known as: Aricept

Drug: Donepezil

Placebos DRUG

Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial. Participants also received 2 weeks of memory training at weeks 13-14

Also known as: Control

Placebo (Control)

Eligibility Criteria

• Age: 55 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Study 1 only:
• Global Clinical Dementia Rating (CDR) 0.0 or 0.5, at least 1 Box score = 0.5 and none \> 0.5;
• Laboratory normal B12, RPR, and Thyroid Function Tests or without any clinically significant abnormalities that would be expected to interfere with the study, plus general clinical chemistry and complete blood count.
• ECG without clinically significant abnormalities that would be expected to interfere with the study
• Study 1 and Study 2:
• Mini-Mental Exam score between 24 and 30 (inclusive);
• General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's Disease cannot be made by the site physician at the time of the screening visit;
• Permitted medications stable for at least 1 month prior to screening. In particular: a) Subjects may take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 2 years). b) Estrogen replacement therapy is permissible. c) Ginkgo biloba is permissible, but discouraged.
• Hamilton Depression Score less than or equal to 12 on the 17-item scale.
• Visual and auditory acuity adequate to allow neuropsychological testing.
• General health good with no additional diseases expected to interfere with the study.
• Women two years post-menopausal or surgically sterile.

You may not qualify if:

• Any significant neurologic disease such as Possible and Probable AD, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
• Major depression or another major psychiatric disorder as described in DSM IV within the past 2 years. History of schizophrenia (DSM IV criteria). Psychotic features, agitation or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.
• History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
• Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including:
• History of systemic cancer within the last 5 years (non-metastatic skin cancers are acceptable).
• History of myocardial infarction within the past year or unstable or severe cardiovascular disease including angina or CHF with symptoms at rest.
• Clinically significant obstructive pulmonary disease or asthma.
• Clinically significant and unstable gastrointestinal disorder such as ulcer disease or a history of active or occult gastrointestinal bleeding within two years.
• Insulin-requiring diabetes or uncontrolled diabetes mellitus.
• Uncontrolled hypertension (systolic BP greater than 170 or diastolic greater than 100).
• History of clinically significant liver disease, coagulopathy, or vitamin K deficiency within the past 2 years.
• Use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4 weeks prior to screening. b) Use of anti-Parkinsonian medications (e.g. Sinemet, amantadine, bromocriptine, pergolide and selegiline) within 2 months prior to screening. c) Use of neuroleptics or narcotic analgesics within 4 weeks prior to screening. d) Use of long-acting benzodiazepines or barbiturates within 4 weeks prior to screening. e) Use of short-acting anxiolytics or sedative hypnotics more frequently than 2 times per week within 4 weeks prior to screening (note: sedative agents should not be used within 72 hours of screening). f) Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the 4 weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable). g) Use of systemic corticosteroids within 3 months prior to screening. h) Medications with significant cholinergic or anticholinergic side effects (e.g. pyridostigmine, tricyclic antidepressants, meclizine, and oxybutynin) within 4 weeks prior to screening. i) Use of anti-convulsants (e.g. Phenytoin, Phenobarbital, Carbamazepine) within 2 months prior to screening. j) Use of warfarin (Coumadin) within 4 weeks prior to screening.
• Any prior use of any FDA approved medications for the treatment of Alzheimer's Disease (e.g. tacrine, donepezil, or other newly approved medications).
• Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening.

Sponsors & Collaborators

• Stanford University: lead
• National Institute of Mental Health (NIMH): collaborator

Study Sites (1)

VA Palo Alto Health Care System

Palo Alto, California, 94304, United States

Location

MeSH Terms

Interventions

Donepezil

Intervention Hierarchy (Ancestors)

Indans; Indenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Polycyclic Compounds

Study Officials

• Jerome A Yesavage

  Stanford University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: May 11, 2010
• First Posted: December 9, 2016
• Study Start: April 1, 2000
• Primary Completion: September 1, 2007
• Study Completion: September 1, 2007
• Last Updated: February 10, 2017

Record last verified: 2016-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)